GGrantIndex
← Leaderboards

Sofia Diana Merajver

University Of Michigan At Ann Arbor

$3,387,621
Attributed
$4,143,300
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $388.4K · FY200524
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$4,143,300 · 6

By mechanism

R01$2,230,621 · 1
R33$1,138,128 · 1
R21$774,345 · 2
M01$206 · 2

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Copper

Research focus

CopperMolecularTumorNeoplasm MetastasisPathway InteractionsMetastasisAngiogenesis InhibitorsIn VivoNeoplastic CellPreventionBreast NeoplasmsGrantPreventCancer CellPredictive MarkerScid MouseMouse ModelMalignant NeoplasmsLaboratory MouseLesionDisease /Disorder ModelIn VitroFutureMalignant Breast Neoplasm

Grant awards (18)

Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence$369,018
R33 · FY2024 · CA · contact PI
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence$380,672
R33 · FY2023 · CA · contact PI
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence$388,438
R33 · FY2022 · CA · contact PI
Artificial Intelligence driven prediction of brain metastasis from primary tumor sites at diagnosis$182,325
R21 · FY2021 · CA · contact PI
Artificial Intelligence driven prediction of brain metastasis from primary tumor sites at diagnosis$218,790
R21 · FY2020 · CA · contact PI
Integrative signaling to increase efficacy of targeted therapies for triple negative breast cancer$169,650
R21 · FY2018 · CA · contact PI
Integrative signaling to increase efficacy of targeted therapies for triple negative breast cancer$203,580
R21 · FY2017 · CA · contact PI
Prevention of Mammary Cancer in Her-2neu Transgenic Mice$265,557
R01 · FY2007 · CA · contact PI
Prevention of Mammary Cancer in Her-2neu Transgenic Mice$273,703
R01 · FY2006 · CA · contact PI
Prevention of Mammary Cancer in Her-2neu Transgenic Mice$362,537
R01 · FY2005 · CA
Prevention of Mammary Cancer in Her-2neu Transgenic Mice$280,712
R01 · FY2004 · CA
Prevention of Mammary Cancer in Her-2neu Transgenic Mice$280,914
R01 · FY2003 · CA
PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE$237,244
R01 · FY2002 · CA
STUDY OF TETRATHIOMOLYBDATE (TM) AS A DECOPPERING AND ANTIANGIOGENESIS OF CANCER$0
M01 · FY2002 · RR
PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE$268,349
R01 · FY2001 · CA
PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICE$261,605
R01 · FY2000 · CA
FAMILIES WITH GENETIC SUSCEPTIBILITY TO BREAST CANCER$206
M01 · FY2000 · RR
STUDY OF TETRATHIOMOLYBDATE (TM) AS A DECOPPERING AND ANTIANGIOGENESIS OF CANCER$0
M01 · FY2000 · RR